TargetBeta
SYK
spleen associated tyrosine kinase · SH2 domain containing
2 programs in company-led studies act on SYK, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| TQB3473 | Sino Biopharmaceutical | phase 3 | 32 running | – | the company's pipeline |
| sovleplenibrule | HUTCHMED | phase 3 | 141 running | – | ChEMBL |
Conditions their studies are in
- Purpura, Thrombocytopenic, Idiopathic, 2 programs
- Anemia, Hemolytic, Autoimmune, 1 program
- Hematologic Neoplasms, 1 program
- Lymphoma, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Thrombocytopenia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027TQB3473 · Sino Biopharmaceutical · phase 3 · NCT06900920
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.